Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
Investing.com -- Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported second quarter financial results that significantly exceeded analyst expectations, driven by strong performance across its commercial portfolio, particularly its international business and PFIC launch. The stock surged 8.6% following the announcement.
The biopharmaceutical company posted a second quarter loss of $0.12 per share, beating analyst estimates of a $0.33 loss by $0.21. Revenue reached $127.8 million, substantially outpacing the consensus estimate of $107.4 million and representing a 64% increase from the $77.9 million reported in the same quarter last year.
LIVMARLI net product sales were $88.2 million, showing remarkable 87% growth YoY, while Bile Acid Medicines generated $39.6 million, up 30% from the second quarter of 2024. The strong performance prompted Mirum to raise its full-year revenue guidance to between $490 million and $510 million.
"Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch," said Chris Peetz, chief executive officer of Mirum. "The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients than we initially projected, allowing us to raise guidance with confidence."
The company also highlighted progress in its pipeline, with the VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment this quarter, with topline data anticipated in the second quarter of 2026.
As of June 30, 2025, Mirum reported a strong financial position with unrestricted cash, cash equivalents, and investments of $321.7 million, up from $292.8 million at the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.